Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AD/PD 2026

AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases

17–21 March 2026 | Copenhagen, Denmark

The AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases took place in Copenhagen, Denmark, from 17-21 March, 2026. This conference showcased the latest advances in treatment, translational research, and clinical trials across Alzheimer’s, Parkinson’s, and related neurological disorders.

View all videos

A study using CSF proteomics to define the natural history of sporadic AD

Betty Tijms • 18 Mar 2026

Mirodenafil in early Alzheimer’s disease: updates from the Phase III POLARIS-AD trial

Sharon Sha • 19 Mar 2026

Leveraging omics for precision drug development in neurodegenerative diseases

Ornit Chiba-Falek • 18 Mar 2026

Advances in epigenome-based therapies targeting APOE in AD

Ornit Chiba-Falek • 18 Mar 2026

Mechanisms of cognitive resilience and brain health

James Galvin • 10 Mar 2026

How do biomarkers of AD differ among diverse populations?

Sid O’Bryant • 20 Mar 2026

Findings from the Phase III APOLLOE4 trial of valiltramiprosate in APOE4/4 early AD

David Watson • 19 Mar 2026

Risk of ARIA in APOE4/4 AD and insights from the APOLLOE4 trial of valiltramiprosate

David Watson • 19 Mar 2026

Sleep-based interventions being explored to preserve brain health and delay the progression of AD

Arsenio Paez • 19 Mar 2026

Advancing precision prevention strategies in Alzheimer’s disease

Audrey Gabelle • 25 Mar 2026

Should amyloid and tau pathology be targeted together to treat Alzheimer’s disease?

Robert Vassar • 20 Mar 2026

The ongoing role of neuropathology to study neurodegenerative diseases in the biomarker era

Lea Grinberg • 19 Mar 2026